drugset / Trial / NCT02462629

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

NCT02462629 ↗

Phase 1 Completed 29 enrolled Blaze Bioscience Inc.
NaSingle-groupOpen-labelOther

Summary

Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. The investigators hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as they operate. This is a safety study to assess the safety of BLZ-100 in pediatric patients with central nervous system tumors.

Timeline

Start
2015-06
Primary completion
2018-07
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Subject tozuleristide Diagnostic / imaging agent — —